All In Biotech

Drug Trial Radar · NCT06505031

A Study of TAK-861 in People With Narcolepsy Type 1

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Oct 8, 2024

Primary completion

Jun 4, 2025

Study completion Jun 4, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jul 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms and daily life functions; and to learn about the safety of TAK-861.

Conditions

  • Narcolepsy Type 1

Interventions

  • TAK-861Drug

    Oral tablet.

  • PlaceboDrug

    TAK-861-matching placebo tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake TrialsTime frame: Baseline, Week 12
  2. Change From Baseline to Week 12 in ESS Total ScoreTime frame: Baseline, Week 12

Locations

28 sites in 11 countries. Site status is shown where the registry gives one.

  • Takeda Site 1

    Glebe, New South Wales, Australia

  • Takeda Site 22

    Linz, Austria

  • Takeda Site 2

    Alken, Belgium

  • Takeda Site 3

    Erpent, Belgium

  • Takeda Site 25

    Ghent, Belgium

  • Takeda Site 24

    Leuven, Belgium

  • Takeda Site 23

    Liège, Belgium

  • Takeda Site 26

    Guangdong, China

  • Takeda Site 4

    Beijing, Beijing Municipality, China

  • Takeda Site 27

    Zhengzhou, Henan, China

  • Takeda Site 28

    Shanghai, Shanghai Municipality, China

  • Takeda Site 20

    Helsinki, Finland

  • Takeda Site 21

    Tampere, Finland

  • Takeda Site 6

    Bron, France

  • Takeda Site 14

    Marseille, France

  • Takeda Site 5

    Montpellier, France

  • Takeda Site 15

    Nantes, France

  • Takeda Site 16

    Léon, Bordeaux, France

  • Takeda Site 7

    Bologna, Italy

  • Takeda Site 17

    Pozzilli, Italy

  • Takeda Site 8

    Roma, Italy

  • Takeda Site 9

    Krakow, Poland

  • Takeda Site 12

    Seoul, South Korea

  • Takeda Site 11

    Seoul, Daegu, South Korea

  • Takeda Site 10

    Suwon, Gyeonggi-do, South Korea

  • 28003

    Barcelona, Spain

  • Takeda Site 13

    Madrid, Spain

  • Takeda Site 19

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.